Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

YPrime Survey Reveals Challenges and Opportunities for Streamlining Oncology Trials with eCOA

By: Y-Prime, LLC via GlobeNewswire

April 03, 2024 at 08:00 AM EDT

MALVERN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- YPrime, the leading pioneer in clinical trial technology, today revealed findings from a comprehensive survey of oncology clinical research stakeholders. The report detailing and analyzing the findings, Decreasing the Burden of Oncology Clinical Trials with eCOA, sheds light on the specific challenges and opportunities surrounding electronic clinical outcome assessment (eCOA) use in oncology trials.

While all clinical trials share similarities, oncology trials present distinct complexities. These include diverse cancer types, treatment modalities, patient populations, endpoints, and lengthy follow-up periods.

Key Survey Findings:

Patient recruitment and retention remain top concerns: 81% of respondents identified this as a major challenge.
Timelines and delays are pervasive: 68% of participants cited this as a concern, highlighting the pressure to accelerate time-to-market.
Managing complexity is crucial: 50% of respondents emphasized the need for systems capable of handling complex study designs and protocol amendments.

"This survey's findings highlight the crucial role eCOA technology can play in addressing the unique challenges of oncology research," said Mike Hughes, Chief Product Officer at YPrime. "By improving patient engagement, streamlining data collection, and enabling real-time insights, eCOA platforms can significantly reduce risk and uncertainty in oncology trials. This translates to faster time-to-market for new cancer treatments, ultimately benefiting patients needing effective therapies."

YPrime's eCOA solves for certainty through deep oncology expertise and a validated library, ensuring a smooth and efficient startup and amendment implementation process. This translates to fewer delays and faster timelines, while enabling a seamless user experience.

The report also explores how eCOA platforms can help address these priorities:

Enhanced patient-centricity: 66% of respondents identified eCOA's ability to collect vital patient-reported outcomes (PROs) and manage complex questionnaires as key benefits.
Reduced patient burden: 66% of participants highlighted the value of eCOA in minimizing patient time spent at clinical sites.
Flexibility and adaptability: Survey responses emphasized the need for eCOA platforms that can adapt to the ever-evolving nature of oncology research.

Within several questions, survey participants identified concerns regarding the time required for study start-up and protocol amendment implementation. These delays can significantly impact overall clinical trial timelines.

For a complete analysis of the survey findings and a deeper dive into how eCOA can optimize your oncology trials, download the complimentary report, Decreasing the Burden of Oncology Clinical Trials with eCOA.

About YPrime
At YPrime, we pioneer solutions that streamline the clinical trial journey, increasing certainty from study design to data lock. We provide eConsent, eCOA, IRT, and patient engagement solutions, enabling speed, flexibility, and certainty. To learn more, email marketing@yprime.com or visit www.yprime.com.

Media Contact
Terry Rehm
Head of Thought Leadership and Public Relations, YPrime
trehm@yprime.com
862-288-0329

An image accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a4f32d3b-9475-487d-9d7a-ddae78fa6655